ABSTRACT

According to global pandemic of novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has created an urgent need for effective1 .Its unique structural features allow high concentrations of the active triphosphate metabolite to be delivered intracellularly and it evades proofreading to successfully inhibit viral RNA synthesis. 1 In pre-clinical models, remdesivir has demonstrated potent antiviral activity against diverse human and zoonotic ?coronaviruses, including SARS-CoV-2. In this article, we critically review available data on remdesivir with an emphasis on biochemistry, pharmacology, pharmacokinetics, Remdesivir (formerly GS-5734) is a nucleoside analogue pro-drug currently being evaluated in COVID-19 clinical trials. Remdesviris an investigational nucleotide analogue with broad-spectrum antiviral activity 1 .currently it is not approved anywhere globally for any use. Remdesivir has demonstrated in vitro and in vivo activity in various animal models against the viral activity of pathogens MERS and SARS, which are also coronaviruses and are structurally similar to COVID-191. The limited preclinical data is available on remdesivir in MERS and SARS indicate that remdesivir may have potential activity against CORONA virus. Remdesivir is an experimental medicine and it doesn’t have any safety and efficacy . This Prodrug having demostrated ability to inhibit SARS-CoV-2 replication, which support its clinical evaluation for COVID-19 treatment.2
Publication date: 25/01/2022

https://ijbpas.com/pdf/2022/January/MS_IJBPAS_2022_JAN_SPCL_2_2029.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2022/11.1.2029